ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0021187

hyperlipidemia

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. hyperlipidemia. Diseases, record MONDO_0021187. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021187

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
hyperlipidemia
Open Targets
Open Targets ID
MONDO_0021187
Open Targets
Other names
Elevated lipids in blood, Hyperlipemia, Hyperlipemias, Hyperlipidemias, Lipemia, Lipemias, Lipidemia, Lipidemias, hyperlipidemia (disease)
Open Targets
MeSH
D006949
MeSH
Highest stage of its drugs
Approval, for 16 of its 62 drugs, from DailyMed, FDA, PMDA and TTD
Open Targets

Drugs62

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ATORVASTATINCHEMBL1487Small moleculeApprovalTTD151414Drugs and targets
SIMVASTATINCHEMBL1064Small moleculeApprovalDailyMed12899Drugs and targets
EZETIMIBECHEMBL1138Small moleculeApprovalDailyMed2255Drugs and targets
FENOFIBRATECHEMBL672Small moleculeApprovalPMDA644Drugs and targets
NIACINCHEMBL573Small moleculeApprovalDailyMed1933Drugs and targets
ROSUVASTATIN CALCIUMCHEMBL1744447Small moleculeApprovalDailyMed2011Drugs and targets
PITAVASTATIN CALCIUMCHEMBL1237061Small moleculeApprovalDailyMed211Drugs and targets
ATORVASTATIN CALCIUMCHEMBL393220Small moleculeApprovalDailyMed7100Drugs and targets
AMLODIPINE BESYLATECHEMBL1200402Small moleculeApprovalDailyMed700Drugs and targets
ICOSAPENT ETHYLCHEMBL2095209Small moleculeApprovalPMDA100Drugs and targets

1 to 10 of 62

See all 62 drugs

Targets82

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductase10HMG-CoA reductase inhibitorApprovalhttps://conductscience.org/library/genes/3156Drugs and targets
AGTR1Type-1 angiotensin II receptor5Type-1 angiotensin II receptor antagonistPhase 3https://conductscience.org/library/genes/185Drugs and targets
PCSK9Proprotein convertase subtilisin/kexin type 94Subtilisin/kexin type 9 inhibitorPhase 3https://conductscience.org/library/genes/255738Drugs and targets
ANGPTL3Angiopoietin like 3 (ANGPTL3) mRNA2Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitorUnknownhttps://conductscience.org/library/genes/27329Drugs and targets
ASGR1Asialoglycoprotein receptor 12Asialoglycoprotein receptor 1 binding agentUnknownhttps://conductscience.org/library/genes/432Drugs and targets
CACNA1CVoltage-gated L-type calcium channel2Voltage-gated L-type calcium channel blockerApprovalhttps://conductscience.org/library/genes/775Drugs and targets
CACNA1DVoltage-gated L-type calcium channel2Voltage-gated L-type calcium channel blockerApprovalhttps://conductscience.org/library/genes/776Drugs and targets
CACNA1FVoltage-gated L-type calcium channel2Voltage-gated L-type calcium channel blockerApprovalhttps://conductscience.org/library/genes/778Drugs and targets
CACNA1SVoltage-gated L-type calcium channel2Voltage-gated L-type calcium channel blockerApprovalhttps://conductscience.org/library/genes/779Drugs and targets
GLP1RGlucagon-like peptide 1 receptor2Glucagon-like peptide 1 receptor agonistApprovalhttps://conductscience.org/library/genes/2740Drugs and targets

1 to 10 of 82

See all 82 targets

Trials82

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01854918Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed DyslipidemiaPhase 33,6812019-06-11Hyperlipidemia and Mixed DyslipidemiaEVOLOCUMABIts record names the diseaseClinicalTrials.gov
NCT02666664Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)Phase 32,2302020-04-20Hypercholesterolemia, Atherosclerotic Cardiovascular DiseasesBEMPEDOIC ACIDIts record names the diseaseClinicalTrials.gov
NCT01968967Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsPhase 32,1392017-07-24HyperlipidemiaBOCOCIZUMABIts record names the diseaseClinicalTrials.gov
NCT00271817To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)Phase 31,2202009-08-03HypercholesterolemiaEZETIMIBE, NIACIN, SIMVASTATINIts record names the diseaseClinicalTrials.gov
NCT02662569Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed DyslipidemiaPhase 39862019-01-11Diabetes, Hyperlipidemia, Mixed DyslipidemiaATORVASTATIN, EVOLOCUMABIts record names the diseaseClinicalTrials.gov
NCT01516879Durable Effect of PCSK9 Antibody CompARed wiTh placEbo StudyPhase 39052015-09-29HypercholesterolemiaEVOLOCUMABIts record names the diseaseClinicalTrials.gov
NCT02991118Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular RiskPhase 37792020-04-27Hypercholesterolemia, Atherosclerotic Cardiovascular DiseaseBEMPEDOIC ACIDIts record names the diseaseClinicalTrials.gov
NCT01674712
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
Phase 35752014-10-30DyslipidemiaFENOFIBRATE, SIMVASTATINIts record names the diseaseClinicalTrials.gov
NCT02833844Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed DyslipidemiaPhase 34672020-07-21Subjects With Hyperlipidemia, Dyslipidemia and HIV InfectionEVOLOCUMABIts record names the diseaseClinicalTrials.gov
NCT01953328Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular RiskPhase 34092015-12-23Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular EventsEVOLOCUMABIts record names the diseaseClinicalTrials.gov

1 to 10 of 82

See all 82 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Bempedoic Acid vs Placebo: deaths from any cause13 of 1,4872 of 7422,229NCT02666664Trial comparisons
Bempedoic Acid vs Placebo: serious adverse events216 of 1,487104 of 7422,229NCT02666664Trial comparisons
Evolocumab vs Placebo: serious adverse events33 of 59913 of 302901NCT01516879Trial comparisons
Bempedoic Acid vs Placebo: deaths from any cause6 of 5222 of 257779NCT02991118Trial comparisons
Bempedoic Acid vs Placebo: serious adverse events106 of 52248 of 257779NCT02991118Trial comparisons
Orlistat vs Placebo: serious adverse events0 of 1002 of 100200NCT00001723Trial comparisons
Adverse Events Were Not Collected vs None: serious adverse events0 of 390 of 3978NCT02304926Trial comparisons
Atorvastatin 10 mg vs Pravastatin 80 mg: serious adverse events0 of 170 of 1936NCT00166036Trial comparisons

Papers from its trials53

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
33261312RESULT1PubMed
30865796RESULT1PubMed
29066265RESULT1PubMed
28844508RESULT1PubMed
22264573RESULT1PubMed
20824151RESULT1PubMed
20008831RESULT1PubMed
18468736RESULT1PubMed
18018771RESULT1PubMed
17434848RESULT1PubMed

1 to 10 of 53

See all 53 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021187

GET https://conductscience.org/api/diseases/v1/MONDO_0021187/drugs?page=2

API referenceFor AI assistants